|
|
67th Annual Meeting Abstracts
Evaluation of the Prostate Cancer Prevention Trial Risk Calculator in a High-Risk Screening Population
David J Kaplan, Stephen A Boorjian, *Karen Ruth, *Brian L Egleston, David Y.T. Chen, Rosalia Viterbo, Robert G. Uzzo, *Mark K. Buyyounouski, *Susan Raysor, *Veda N. Giri
Fox Chase Cancer Center, Philadelphia, PA
Introduction:
Clinical factors in addition to PSA have been evaluated to improve risk assessment for prostate cancer (CaP). The Prostate Cancer Prevention Trial (PCPT) risk calculator provides an assessment of CaP risk based on age, PSA, race, prior biopsy, and family history. This study evaluated the risk calculator in a screening cohort of young, racially-diverse high risk men with a low baseline PSA.
Materials & Methods:
Our Prostate Risk Assessment Program (PRAP) enrolls men age 35-69 who are African-American, have a family history of CaP, or have a known BRCA1/2 mutation. PCPT risk scores were determined for PRAP participants, and were compared to observed CaP rates.
Results:
624 patients fit inclusion criteria, including 382 (61.2%) African-American men and 375 (60%) men with a family history of CaP. Median age was 49.0 years (range 34.0-69.0), and median PSA was 0.9 (range 0.1-27.2). PCPT risk score correlated with CaP diagnosis, as the median baseline risk score in patients diagnosed with CaP was 31.3%, versus 14.2% in patients not diagnosed with CaP (p<0.0001). The PCPT calculator similarly stratified the risk of diagnosis of Gleason score ≥ 7 disease, as the median risk score was 36.2% in patients diagnosed with Gleason ≥ 7 CaP versus 15.2% in all other participants (p<0.0001).
Conclusions:
The PCPT risk calculator score was found to stratify CaP risk in a cohort of young, primarily African-American patients with a low baseline PSA. These results support the application of this predictive tool for CaP risk assessment in high-risk men.
|
|
